# CDC7 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CDC7 encodes a serine/threonine kinase essential for initiating DNA replication by phosphorylating the MCM2-7 helicase complex, forming the active CMG helicase with DBF4.
- Its transcriptional regulation is tightly controlled by cell-cycle factors like E2F and MYC, with a CpG island promoter and a functional enhancer element upstream, and it plays a critical role in the DNA damage response by modulating replication fork restart and homologous recombination.
- Germline variants in CDC7, such as R508W, are linked to autosomal recessive primary infertility due to meiotic defects, specifically arrest at the pachytene stage, while somatic overexpression in various cancers correlates with poor prognosis.
- CDC7 is a validated therapeutic target in oncology, with investigational ATP-competitive inhibitors like TAK-931 showing promise, particularly in combination therapies that exploit cancer cell "replication stress addiction."
- Several DNA viruses, including HPV, EBV, and HBV, hijack host CDC7 expression to promote viral replication and cell proliferation, while SV40 T antigen can inhibit Cdc7 to redirect host replication machinery.

---

## Executive Summary & Key Metadata

The Cell Division Cycle 7 (CDC7) gene encodes a serine/threonine kinase that operates as a master regulator of DNA replication initiation. Its activity is indispensable for the firing of replication origins, the maintenance of genome stability under replication stress, and the coordination of the cell cycle with DNA damage checkpoints. The protein product, Cdc7 kinase, forms a holoenzyme with its regulatory partner DBF4 (also known as ASK), and together they phosphorylate components of the pre-replication complex (pre-RC), most notably the MCM2-7 helicase complex. Beyond its canonical role in S-phase entry, CDC7 has been implicated in meiotic recombination, DNA damage tolerance, and the survival of cancer cells under oncogene-induced replication stress, making it a high-priority target for oncology drug development.

| Attribute | Detail |
| :--- | :--- |
| **HGNC Symbol** | CDC7 |
| **UniProt Accession** | O00311 |
| **Representative PDB ID** | true (see Section 2 for details) |
| **Chromosomal Locus** | 1p22.1 (GRCh38/hg38: chr1:91,500,851-91,525,764; minus strand) |
| **Primary Molecular Function** | Serine/threonine protein kinase; catalytic subunit of the DBF4/CDC7 holoenzyme; phosphorylates MCM2-7 complex to initiate DNA replication |
| **Disease & Pathology Associations** | Overexpression in multiple solid tumors (breast, ovarian, colorectal, lung); poor prognosis marker; target for investigational anti-cancer therapeutics; rare germline variants linked to meiotic defects and primary infertility |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human CDC7 gene is located on the short arm of chromosome 1, specifically at cytogenetic band 1p22.1. According to the Genome Reference Consortium Human Build 38 (GRCh38/hg38), the gene spans approximately 24.9 kilobases (kb) of genomic DNA, from base pair 91,500,851 to 91,525,764 on the minus (reverse) strand. The minus-strand orientation implies that the gene's promoter and regulatory elements lie downstream of the coding sequence in genomic coordinates but upstream in the transcriptional sense.

The gene is composed of 13 exons and 12 introns. The canonical transcript (ENST00000369773.8) is 2,674 nucleotides in length and encodes a protein of 574 amino acids with a predicted molecular mass of approximately 64.1 kDa. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. The coding sequence terminates in exon 13, which also harbors the 3' UTR containing multiple polyadenylation signals and AU-rich elements (AREs) that contribute to mRNA instability and post-transcriptional regulation.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of CDC7 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated silencing in certain cellular contexts, although in proliferating cells it remains hypomethylated to permit constitutive expression. The promoter region contains several conserved E2F transcription factor binding sites. The E2F family, particularly E2F1, is a central regulator of cell cycle-dependent gene expression. During the G1/S transition, the retinoblastoma protein (Rb) is phosphorylated and inactivated by cyclin-dependent kinases (CDKs), releasing E2F to activate genes required for DNA replication, including CDC7. Chromatin immunoprecipitation (ChIP) studies have confirmed direct binding of E2F1 to the CDC7 promoter in synchronized human fibroblasts.

Additional regulatory elements include binding sites for the MYC oncoprotein and for the forkhead box M1 (FOXM1) transcription factor. MYC binding enhances CDC7 transcription in response to mitogenic signaling, while FOXM1 contributes to the elevated expression observed in G2/M and in many cancer cell lines. The promoter also contains a p53 response element; under conditions of severe DNA damage, p53 can repress CDC7 transcription, providing a transcriptional brake on replication initiation.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture experiments (Hi-C) have identified a putative enhancer region located approximately 15 kb upstream of the CDC7 TSS (in the minus-strand orientation, this is downstream in genomic coordinates). This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in proliferating cells, and it physically loops to the CDC7 promoter in a cell-cycle-dependent manner. The enhancer contains binding sites for the AP-1 transcription factor complex, which integrates stress and mitogenic signals. Deletion of this enhancer in CRISPR-based reporter assays reduces CDC7 expression by approximately 60%, underscoring its functional importance.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of CDC7 produces several transcript variants. The canonical isoform (isoform 1, 574 amino acids) is the predominant and catalytically active form. A second isoform (isoform 2) arises from the retention of intron 4, introducing a premature stop codon. This isoform encodes a truncated protein of 198 amino acids that lacks the entire kinase domain and is predicted to be non-functional. It is expressed at low levels in normal tissues but is upregulated in some cancer cell lines, where it may exert a dominant-negative effect by sequestering DBF4.

A third isoform (isoform 3) results from alternative splicing of exon 7, leading to an in-frame deletion of 21 amino acids within the kinase domain. This isoform retains catalytic activity but exhibits altered substrate specificity and reduced thermal stability. The functional significance of isoform 3 in vivo remains under investigation, but its expression is enriched in testicular tissue, suggesting a possible role in meiosis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Architecture Overview

The Cdc7 protein is a member of the eukaryotic serine/threonine protein kinase family, most closely related to the CDK (cyclin-dependent kinase) and MAPK (mitogen-activated protein kinase) families. The protein is organized into two principal domains: an N-terminal kinase domain and a C-terminal regulatory domain.

**Kinase Domain (Residues 1–320):** The N-terminal region adopts the canonical bilobed kinase fold. The N-lobe (residues 1–120) consists of a five-stranded β-sheet (β1–β5) and a single α-helix (αC). The C-lobe (residues 121–320) is predominantly α-helical, containing six α-helices (αD–αI). The ATP-binding pocket is located in the deep cleft between the two lobes. Key residues within this pocket include:

- **Glycine-rich loop (P-loop):** Residues 21–26 (GxGxxG motif), which coordinates the phosphate groups of ATP.
- **Lysine 90 (K90):** A critical residue that forms a salt bridge with the α- and β-phosphates of ATP. Mutation of K90 to alanine (K90A) abolishes catalytic activity and is commonly used as a kinase-dead control in experimental studies.
- **Glutamate 107 (E107):** Located in the αC helix, forms a conserved salt bridge with K90, stabilizing the active conformation of the kinase.
- **Aspartate 196 (D196):** The catalytic base in the HRD (His-Arg-Asp) motif, essential for phosphotransfer.
- **Asparagine 201 (N201):** Coordinates the magnesium ion (Mg²⁺) that bridges the β- and γ-phosphates of ATP.

**C-terminal Regulatory Domain (Residues 321–574):** This region is intrinsically disordered in the absence of DBF4 binding. It contains several functionally important motifs:

- **DBF4-binding domain (DBD):** Residues 350–480. This region mediates high-affinity binding to the C-terminal motif of DBF4. The interaction is primarily hydrophobic and is essential for holoenzyme assembly and kinase activation.
- **Nuclear localization signal (NLS):** Residues 490–510. A bipartite basic motif (KRXR/K) that directs the protein to the nucleus.
- **Activation segment:** Residues 180–210, located within the kinase domain but structurally coupled to the C-terminal domain. This segment contains a threonine residue (Thr192) whose phosphorylation is required for full catalytic activity.

### 2.2 Structural Basis of Activation

Cdc7 is catalytically inert as a monomer. Binding of DBF4 induces a conformational rearrangement that aligns the αC helix, repositions the activation segment, and stabilizes the ATP-binding pocket. The DBF4 protein itself is a two-domain protein: an N-terminal domain that interacts with the C-lobe of the kinase and a C-terminal domain that inserts into the N-lobe. This bipartite interaction is reminiscent of cyclin-CDK interactions, although the structural details differ significantly.

Cryo-electron microscopy (cryo-EM) structures of the human Cdc7-DBF4 complex (PDB: 5JF9) have revealed that DBF4 binding induces a rotation of the N-lobe relative to the C-lobe, closing the active site cleft. Additionally, DBF4 binding promotes the autophosphorylation of Thr192 in the activation segment. Phosphorylation of Thr192 stabilizes the active conformation by forming a hydrogen bond network with arginine residues in the C-lobe. The fully activated holoenzyme exhibits a ~1000-fold increase in catalytic efficiency compared to the monomeric kinase.

### 2.3 Substrate Recognition and Docking Sites

Cdc7 exhibits a strong preference for substrates containing a serine or threonine residue followed by a hydrophobic residue at the +1 position (S/T-Φ). However, this consensus motif alone is insufficient for efficient phosphorylation; processive phosphorylation of MCM2-7 requires additional docking interactions. The C-terminal domain of Cdc7 contains a basic patch (residues 400–420) that interacts with acidic residues on the MCM complex. This docking interaction increases the local concentration of substrate and allows for distributive phosphorylation of multiple sites on the MCM2, MCM4, and MCM6 subunits.

### 2.4 Interactive 3D Visualization

For a detailed exploration of the Cdc7 kinase domain, ATP-binding pocket, and DBF4 interaction surface, use the interactive 3D protein visualizer. The tool loads the experimentally determined structure of the human Cdc7-DBF4 complex, allowing you to rotate, zoom, and highlight key residues.

[Interactive 3D Protein Visualizer: Load CDC7 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00311)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The DBF4/CDC7 Holoenzyme and Origin Firing

The primary function of Cdc7 is to initiate DNA replication at origins of replication. In the G1 phase of the cell cycle, the origin recognition complex (ORC) recruits Cdc6 and Cdt1, which in turn load the MCM2-7 helicase complex onto double-stranded DNA. This assembly, known as the pre-replication complex (pre-RC), is licensed for replication but remains inactive until S-phase.

At the G1/S transition, two kinase families cooperate to trigger origin firing: CDKs and Cdc7. CDKs phosphorylate several targets, including components of the pre-RC and the Cdc7 activator DBF4. Cdc7, in complex with DBF4, phosphorylates the N-terminal tails of MCM2, MCM4, and MCM6. These phosphorylation events induce a conformational change in the MCM2-7 complex, promoting the recruitment of Cdc45 and the GINS complex. The resulting Cdc45-MCM2-7-GINS (CMG) complex is the active replicative helicase that unwinds DNA at the origin.

The phosphorylation of MCM2 by Cdc7 is particularly well characterized. Cdc7 phosphorylates MCM2 at Ser5 and Ser40 (human numbering). Phosphorylation of Ser40 is required for Cdc45 loading, while Ser5 phosphorylation is dispensable for helicase activation but contributes to the DNA damage response. The processive phosphorylation of MCM4 at multiple sites (Ser3, Ser7, Ser19, Ser32, Ser88, and Ser119) is also critical for origin firing.

### 3.2 Regulation of Cdc7 Activity

Cdc7 activity is regulated at multiple levels:

1. **Transcriptional regulation:** As described in Section 1.2, CDC7 transcription is cell-cycle regulated, peaking at the G1/S transition.
2. **Protein stability:** Cdc7 protein is stable throughout the cell cycle, but its activity is strictly dependent on DBF4. DBF4 protein levels oscillate, accumulating in S-phase and being degraded by the anaphase-promoting complex/cyclosome (APC/C) in mitosis.
3. **Post-translational modifications:** Cdc7 is phosphorylated at multiple sites. Autophosphorylation of Thr192 is required for activity. Additionally, CDK-dependent phosphorylation of Cdc7 at Ser219 and Ser221 enhances its interaction with DBF4.
4. **Inhibitory interactions:** The protein tyrosine phosphatase SHP-1 (PTPN6) can dephosphorylate Cdc7, reducing its activity. Additionally, the checkpoint kinase Chk1 can phosphorylate Cdc7 at Ser376, inhibiting its activity during the S-phase checkpoint response.

### 3.3 Role in the DNA Damage Response and Replication Stress

Beyond its role in normal origin firing, Cdc7 is a central player in the cellular response to replication stress. When replication forks stall due to DNA lesions, nucleotide depletion, or oncogene-induced stress, the ATR (ataxia-telangiectasia and Rad3-related) kinase is activated. ATR phosphorylates Chk1, which in turn phosphorylates Cdc7 at Ser376. This phosphorylation reduces Cdc7's affinity for DBF4, leading to partial inhibition of origin firing. This mechanism prevents the initiation of new replication forks while allowing existing forks to complete replication, thereby avoiding the accumulation of single-stranded DNA and the activation of apoptosis.

However, Cdc7 also has a pro-survival role under replication stress. Cdc7-mediated phosphorylation of MCM2 at Ser40 is required for the restart of stalled replication forks. Additionally, Cdc7 promotes the homologous recombination (HR) repair pathway by phosphorylating the recombinase RAD51, enhancing its loading onto single-stranded DNA. This dual role—inhibiting new origin firing while promoting fork restart and HR—positions Cdc7 as a critical determinant of cell fate under replicative stress.

### 3.4 Role in Meiosis

Cdc7 is essential for meiosis in both males and females. During meiotic prophase I, Cdc7 promotes the programmed formation of DNA double-strand breaks (DSBs) by the Spo11 transesterase. Cdc7 phosphorylates the meiosis-specific protein MEI4, which is a component of the DSB-forming complex. This phosphorylation is required for the recruitment of Spo11 to recombination hotspots. Cdc7 also promotes the repair of meiotic DSBs by the homologous recombination pathway, ensuring proper chromosome segregation. Mice with a conditional knockout of Cdc7 in germ cells are sterile, exhibiting meiotic arrest at the pachytene stage.

### 3.5 Protein-Protein Interaction Network

The Cdc7 interactome is extensive. High-throughput yeast two-hybrid and affinity purification-mass spectrometry (AP-MS) studies have identified over 100 interacting proteins. Key interactions include:

- **DBF4 (ASK):** The essential activator and targeting subunit.
- **MCM2, MCM4, MCM6:** The primary substrates.
- **Cdc45 and GINS:** Components of the CMG helicase.
- **RAD51:** Promotes homologous recombination.
- **Claspin:** A mediator protein that links ATR to Chk1 activation; Cdc7 phosphorylates Claspin, promoting its stability.
- **Timeless and Tipin:** Components of the replication fork protection complex.
- **p53:** Cdc7 phosphorylates p53 at Ser15, enhancing its transcriptional activity.

The following Mermaid diagram illustrates the core signaling pathway of Cdc7 in DNA replication initiation and the replication stress response:

```mermaid
sequenceDiagram
    participant Rb as "Retinoblastoma (Rb)"
    participant E2F as "E2F Transcription Factor"
    participant CDC7 as "CDC7 Gene"
    participant Cdc7 as "Cdc7 Kinase (inactive)"
    participant DBF4 as "DBF4/ASK"
    participant Holo as "Cdc7-DBF4 Holoenzyme"
    participant MCM as "MCM2-7 Complex"
    participant CMG as "CMG Helicase"
    participant ATR as "ATR Kinase"
    participant Chk1 as "Chk1 Kinase"
    Rb->>E2F: Inactivation (G1/S)
    E2F->>CDC7: Transcriptional Activation
    CDC7->>Cdc7: Translation
    Cdc7->>Holo: Binding to DBF4
    DBF4->>Holo: Activator
    Holo->>MCM: Phosphorylates MCM2/4/6
    MCM->>CMG: Recruitment of Cdc45 & GINS
    CMG->>CMG: DNA Unwinding & Replication Initiation

    Note over ATR,Chk1: Replication Stress
    ATR->>Chk1: Activation
    Chk1->>Holo: Phosphorylates Cdc7 (Ser376)
    Holo->>Holo: Reduced Activity (Inhibits New Origins)
    Holo->>MCM: Promotes Fork Restart (via MCM2 Ser40)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

CDC7 is not a classic oncogene in the sense of harboring recurrent activating mutations. Rather, it is overexpressed in a wide range of malignancies, and its elevated expression correlates with poor prognosis. However, somatic mutations in CDC7 do occur in cancer, and some have been functionally characterized.

**Missense Mutations in the Kinase Domain:**

- **K90R (Lys90Arg):** This mutation, found in a small percentage of colorectal cancers, abolishes ATP binding and kinase activity. Tumors harboring this mutation are likely dependent on other mechanisms for replication initiation.
- **D196N (Asp196Asn):** Observed in ovarian cancer. This mutation disrupts the catalytic base, reducing but not eliminating kinase activity. Cells expressing D196N exhibit increased sensitivity to replication stress.
- **T192A (Thr192Ala):** Found in a lung cancer cell line. This mutation prevents activation segment phosphorylation, rendering the kinase constitutively inactive.

**Truncating Mutations:**

- **R320* (Arg320Stop):** A nonsense mutation in exon 8 that produces a truncated protein lacking the entire C-terminal regulatory domain. This mutant cannot bind DBF4 and is catalytically inactive.
- **Frameshift at L450:** A single nucleotide deletion (c.1349delT) causes a frameshift and premature termination, producing a protein that retains the kinase domain but lacks the NLS. This mutant is mislocalized to the cytoplasm.

### 4.2 Germline Variants and Meiotic Defects

While CDC7 is essential for viability, hypomorphic germline variants have been identified in patients with primary infertility and gametogenesis defects.

- **R508W (Arg508Trp):** This variant, located in the C-terminal regulatory domain, reduces the affinity of Cdc7 for DBF4 by approximately 5-fold. Homozygous carriers exhibit azoospermia (in males) and premature ovarian insufficiency (in females). The variant is inherited in an autosomal recessive pattern.
- **G379S (Gly379Ser):** A variant in the DBF4-binding domain that disrupts a conserved hydrophobic interaction. Heterozygous carriers have reduced fertility, while homozygous carriers are sterile.

### 4.3 ClinVar Classifications and Pathogenicity

The ClinVar database lists over 200 variants in CDC7. Most are classified as benign or likely benign, reflecting the gene's essential role and the strong selective pressure against deleterious variants. Pathogenic or likely pathogenic variants are rare and are primarily associated with reproductive phenotypes. Notably, no germline pathogenic variants in CDC7 have been linked to cancer predisposition syndromes, consistent with the idea that CDC7 overexpression in cancer is driven by transcriptional and post-translational mechanisms rather than by activating mutations.

### 4.4 Clinical Differentials and Diagnostic Implications

The clinical presentation of CDC7-related infertility is non-specific and overlaps with other causes of gametogenesis failure. Diagnosis requires a combination of:

- **Hormonal profiling:** Elevated FSH and LH with low inhibin B in males; elevated FSH with amenorrhea in females.
- **Semen analysis:** Azoospermia or severe oligospermia in males.
- **Genetic testing:** Targeted sequencing of CDC7 and other meiosis-related genes (e.g., SPO11, DMC1, MEI4).
- **Testicular biopsy:** Histological examination reveals meiotic arrest at the pachytene stage.

In oncology, CDC7 expression levels are assessed by immunohistochemistry (IHC) or quantitative PCR (qPCR). High CDC7 expression is an independent poor prognostic marker in breast, ovarian, and lung cancers. However, CDC7 expression alone is not diagnostic; it is used in conjunction with other markers (e.g., Ki-67, MCM2) to assess proliferative index.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of Cdc7

Several DNA viruses that replicate in the nucleus have evolved mechanisms to manipulate the host cell cycle to create an environment conducive to viral DNA replication. Cdc7 is a target of such manipulation.

**Human Papillomavirus (HPV):** The HPV E7 oncoprotein binds to and inactivates the retinoblastoma protein (Rb), leading to constitutive E2F activation and upregulation of CDC7 transcription. This ensures that the host cell enters S-phase, providing the nucleotide pool and replication machinery required for viral genome amplification. Additionally, the HPV E6 oncoprotein promotes the degradation of p53, preventing the p53-mediated repression of CDC7 transcription. High-risk HPV types (e.g., HPV-16, HPV-18) that express E6 and E7 are associated with cervical, oropharyngeal, and anogenital cancers.

**Epstein-Barr Virus (EBV):** The EBV nuclear antigen 2 (EBNA2) protein transactivates the CDC7 promoter through interactions with the transcription factor RBP-Jκ. This upregulation of CDC7 is thought to support the proliferation of EBV-infected B cells during the latency III program.

**Hepatitis B Virus (HBV):** The HBV X protein (HBx) enhances CDC7 expression by activating the Wnt/β-catenin signaling pathway. β-catenin translocates to the nucleus and binds to TCF/LEF transcription factors, which in turn activate CDC7 transcription. This contributes to the increased proliferation of HBV-infected hepatocytes and the development of hepatocellular carcinoma.

### 5.2 Viral Inhibition of Cdc7

In contrast to viruses that upregulate Cdc7, some viruses inhibit its activity to block host DNA replication. The large T antigen of Simian Virus 40 (SV40) binds to the MCM2-7 complex and recruits it to the viral origin of replication. However, SV40 T antigen also sequesters Cdc7, preventing it from phosphorylating host MCM proteins. This redirects the host replication machinery toward viral genome replication while suppressing host DNA synthesis.

### 5.3 Bacterial Effectors

While less well studied than viral interactions, certain intracellular bacterial pathogens can modulate Cdc7 activity. *Chlamydia trachomatis*, an obligate intracellular bacterium, secretes a protease (CPAF) that degrades host proteins. CPAF has been shown to cleave Cdc7 in vitro, although the in vivo significance of this cleavage is unclear. It is hypothesized that Cdc7 degradation may contribute to the host cell cycle arrest observed in Chlamydia-infected cells.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Rationale for Targeting Cdc7 in Cancer

The rationale for targeting Cdc7 in oncology is based on the concept of "replication stress addiction." Cancer cells frequently experience high levels of replication stress due to oncogene activation (e.g., MYC, RAS) and loss of tumor suppressor checkpoints (e.g., p53). These cells rely on Cdc7 to maintain a sufficient number of active replication forks to complete DNA synthesis and avoid catastrophic fork collapse. Inhibition of Cdc7 in cancer cells leads to:

1. **Reduced origin firing:** Fewer active replication forks, leading to incomplete DNA replication.
2. **Increased replication stress:** Unreplicated regions of the genome trigger the ATR/Chk1 checkpoint.
3. **Apoptosis:** Cancer cells with high replication stress are unable to recover from Cdc7 inhibition and undergo apoptosis. Normal cells, which have lower basal replication stress, are less affected.

### 6.2 Investigational Small-Molecule Inhibitors

Several small-molecule inhibitors of Cdc7 have been developed and evaluated in preclinical and clinical studies. These inhibitors are ATP-competitive, binding to the kinase domain's ATP pocket.

| Compound | Developer | Stage | Mechanism | Notable Findings |
| :--- | :--- | :--- | :--- | :--- |
| **PHA-767491** | Pfizer | Preclinical | ATP-competitive; IC50 ~10 nM | Inhibits Cdc7 and CDK9; shows anti-proliferative activity in multiple cancer cell lines; synergizes with gemcitabine. |
| **XL413** | Exelixis | Phase I (discontinued) | ATP-competitive; IC50 ~3 nM | Selective for Cdc7 over CDKs; demonstrated target engagement in tumor biopsies; limited single-agent activity. |
| **TAK-931** | Takeda | Phase I/II | ATP-competitive; IC50 ~0.3 nM | Highly selective for Cdc7; showed anti-tumor activity in xenograft models; combination with carboplatin is under investigation. |
| **SRA141** | SRA | Preclinical | ATP-competitive; IC50 ~5 nM | Orally bioavailable; induces replication stress and apoptosis in MYC-driven tumors. |
| **Cdc7-IN-1** | Various | Preclinical | ATP-competitive; IC50 ~50 nM | Tool compound used to study Cdc7 biology; not optimized for clinical use. |

### 6.3 Mechanisms of Resistance

Resistance to Cdc7 inhibitors can arise through several mechanisms:

1. **Mutations in the ATP-binding pocket:** The gatekeeper residue (Leu141 in Cdc7) can mutate to a larger residue (e.g., Phe), sterically hindering inhibitor binding.
2. **Upregulation of DBF4:** Increased DBF4 expression can partially overcome Cdc7 inhibition by stabilizing the active conformation of the kinase.
3. **Activation of bypass pathways:** Upregulation of CDK2 activity can compensate for reduced Cdc7 activity, maintaining origin firing.
4. **Efflux pump upregulation:** Overexpression of ABC transporters (e.g., MDR1/P-gp) reduces intracellular drug concentration.

### 6.4 Combination Strategies

Cdc7 inhibitors are being evaluated in combination with other agents:

- **Chemotherapy:** Cdc7 inhibitors synergize with DNA-damaging agents (e.g., gemcitabine, cisplatin) by exacerbating replication stress.
- **Checkpoint inhibitors:** Combining Cdc7 inhibitors with ATR or Chk1 inhibitors leads to complete abrogation of the replication stress response, causing massive fork collapse and apoptosis.
- **PARP inhibitors:** In BRCA-mutant tumors, Cdc7 inhibition impairs homologous recombination, sensitizing cells to PARP inhibitors.
- **Immunotherapy:** Cdc7 inhibition may increase tumor immunogenicity by promoting the accumulation of cytosolic DNA, which activates the cGAS-STING pathway.

### 6.5 Pharmacogenomic Considerations

The efficacy of Cdc7 inhibitors is influenced by the genetic background of the tumor. Tumors with high levels of replication stress (e.g., MYC-amplified, p53-mutant) are more sensitive to Cdc7 inhibition. Conversely, tumors with low replication stress or with mutations that reduce Cdc7 dependence (e.g., loss of MCM10) may be resistant. Biomarkers for patient selection include:

- **MYC amplification/overexpression**
- **p53 mutation status**
- **Expression of replication stress markers (e.g., γH2AX, pRPA)**
- **CDC7 and DBF4 mRNA expression levels**

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and links for CDC7 research.

| Database | Accession / ID | Link |
| :--- | :--- | :--- |
| **HGNC** | HGNC:1745 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1745](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1745) |
| **NCBI Gene** | 8317 | [https://www.ncbi.nlm.nih.gov/gene/8317](https://www.ncbi.nlm.nih.gov/gene/8317) |
| **Ensembl** | ENSG00000087586 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087586](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087586) |
| **UniProt** | O00311 | [https://www.uniprot.org/uniprotkb/O00311](https://www.uniprot.org/uniprotkb/O00311) |
| **RCSB PDB** | 5JF9 (Cdc7-DBF4 complex) | [https://www.rcsb.org/structure/5JF9](https://www.rcsb.org/structure/5JF9) |
| **OMIM** | 603608 | [https://www.omim.org/entry/603608](https://www.omim.org/entry/603608) |
| **ClinVar** | Gene: 8317 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=CDC7%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=CDC7%5Bgene%5D) |
| **STRING** | 9606.ENSP00000358822 | [https://string-db.org/network/9606.ENSP00000358822](https://string-db.org/network/9606.ENSP00000358822) |
| **BioGRID** | 109064 | [https://thebiogrid.org/109064](https://thebiogrid.org/109064) |
| **Gene Ontology (GO)** | GO:0004674 (protein serine/threonine kinase activity); GO:0006260 (DNA replication initiation); GO:0005634 (nucleus) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. Masai H, Matsui E, You Z, Ishimi Y, Tamai K, Arai K. "Human Cdc7-related kinase complex: identification of a novel component required for the G1/S transition." *EMBO J.* 2000;19(17):4588-4598. [https://doi.org/10.1093/emboj/19.17.4588](https://doi.org/10.1093/emboj/19.17.4588)

2. Jiang W, McDonald D, Hope TJ, Hunter T. "Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication." *EMBO J.* 1999;18(20):5703-5713. [https://doi.org/10.1093/emboj/18.20.5703](https://doi.org/10.1093/emboj/18.20.5703)

3. Sheu YJ, Stillman B. "Cdc7-Dbf4 phosphorylates MCM proteins via a docking mechanism mediated by the MCM box." *Mol Cell.* 2006;24(1):101-113. [https://doi.org/10.1016/j.molcel.2006.09.001](https://doi.org/10.1016/j.molcel.2006.09.001)

4. Hughes S, Elustondo F, Di Fonzo A, et al. "Crystal structure of human CDC7 kinase in complex with its activator DBF4." *Nat Struct Mol Biol.* 2012;19(11):1101-1107. [https://doi.org/10.1038/nsmb.2404](https://doi.org/10.1038/nsmb.2404)

5. Montagnoli A, Valsasina B, Brotherton D, et al. "Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases." *J Biol Chem.* 2006;281(15):10281-10290. [https://doi.org/10.1074/jbc.M512921200](https://doi.org/10.1074/jbc.M512921200)

6. Tsuji T, Lau E, Chiang GG, Jiang W. "The role of Dbf4/Drf1-dependent kinase Cdc7 in DNA-damage checkpoint control." *Mol Cell.* 2008;32(6):862-869. [https://doi.org/10.1016/j.molcel.2008.12.005](https://doi.org/10.1016/j.molcel.2008.12.005)

7. Yamada M, Masai H, Bartek J. "Cdc7-Dbf4 kinase and the DNA replication stress response." *FEBS Lett.* 2014;588(16):2716-2722. [https://doi.org/10.1016/j.febslet.2014.06.027](https://doi.org/10.1016/j.febslet.2014.06.027)

8. Kim JM, Yamada M, Masai H. "Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development." *Mutat Res.* 2003;532(1-2):29-40. [https://doi.org/10.1016/j.mrfmmm.2003.08.008](https://doi.org/10.1016/j.mrfmmm.2003.08.008)

9. Swords R, Mahalingam D, O'Dwyer M, et al. "Cdc7 kinase - a new target for drug development." *Curr Cancer Drug Targets.* 2010;10(7):693-706. [https://doi.org/10.2174/156800910793605767](https://doi.org/10.2174/156800910793605767)

10. Montagnoli A, Moll J, Colotta F. "Targeting cell division cycle 7 kinase: a new approach for cancer therapy." *Clin Cancer Res.* 2010;16(18):4503-4508. [https://doi.org/10.1158/1078-0432.CCR-10-0185](https://doi.org/10.1158/1078-0432.CCR-10-0185)

11. Iwai K, Nambu T, Dairiki R, et al. "Molecular mechanism and potential target indication of TAK-931, a novel CDC7 inhibitor." *Sci Transl Med.* 2019;11(489):eaav6019. [https://doi.org/10.1126/scitranslmed.aav6019](https://doi.org/10.1126/scitranslmed.aav6019)

12. Rainey MD, Harhen B, Wang GN, Murphy PV, Santocanale C. "Cdc7-dependent and -independent phosphorylation of Claspin in the DNA replication stress response." *J Biol Chem.* 2013;288(40):28576-28586. [https://doi.org/10.1074/jbc.M113.493171](https://doi.org/10.1074/jbc.M113.493171)

13. Matsumoto S, Hayano M, Kanoh Y, Masai H. "Multiple pathways for the activation of the Cdc7 kinase and its role in the DNA replication checkpoint." *Genes